What Is Retatrutide?
Retatrutide, designated LY-3437943 by Eli Lilly and Company, is an investigational triple-agonist peptide that targets three distinct receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple receptor activity distinguishes it from earlier single and dual-agonist compounds studied in metabolic research.
The compound was first described in preclinical literature by Coskun et al. (2022) in Cell Metabolism, where researchers detailed its design rationale and receptor binding profile. The triple-agonist approach represents a significant evolution in incretin-based peptide research.
Mechanism of Action
Retatrutide engages three receptor pathways simultaneously:
- GLP-1 Receptor: A well-characterized target in metabolic research. GLP-1R activation has been studied extensively for its role in glucose-dependent insulin secretion and gastric motility regulation.
- GIP Receptor: GIP is an incretin hormone released from K-cells in the small intestine. GIPR activation is studied for its complementary role alongside GLP-1R signaling in metabolic pathways.
- Glucagon Receptor: The addition of glucagon receptor agonism is what makes retatrutide unique among investigational peptides in this class. Glucagon signaling is studied for its role in hepatic lipid metabolism and energy expenditure pathways.
This three-receptor approach has generated significant interest in the research community because it addresses multiple metabolic pathways simultaneously, rather than targeting a single receptor in isolation.
Published Research Data
Phase 1 Studies
Early-phase research data published by Eli Lilly established the pharmacokinetic and safety profile of retatrutide in controlled research settings. These studies characterized dose-response relationships and receptor occupancy data that informed subsequent trial designs.
Phase 2 Trial Results
The pivotal Phase 2 data was published by Jastreboff et al. in the New England Journal of Medicine (2023). This 48-week, randomized, double-blind, placebo-controlled study evaluated retatrutide across multiple dose levels. The research demonstrated statistically significant findings across primary and secondary metabolic endpoints compared to placebo.
Key observations from the published data:
- Dose-dependent responses were observed across all measured endpoints
- The highest dose groups showed the most pronounced effects on study endpoints
- The safety profile was consistent with the known class effects of incretin-based peptides
- Gastrointestinal events were the most commonly reported observations, consistent with GLP-1R agonism
Ongoing Phase 3 Program
Eli Lilly initiated the TRIUMPH Phase 3 clinical program to further evaluate retatrutide. As of early 2026, multiple Phase 3 trials are enrolling or actively collecting data. These studies are expected to provide the comprehensive dataset required for regulatory evaluation.
Structural Characteristics
Retatrutide is a 39-amino acid peptide with specific structural modifications designed to achieve its triple-agonist profile:
- Molecular Weight: Approximately 4,605 Da
- Half-Life: Engineered for extended duration through fatty acid acylation, enabling once-weekly research dosing protocols in clinical studies
- Stability: Lyophilized powder form provides optimal stability for research storage at -20°C
How Retatrutide Differs from Other Research Peptides
vs. Semaglutide (Single Agonist)
Semaglutide targets only the GLP-1 receptor. While it has been extensively studied and is well-characterized, it represents a single-pathway approach. Retatrutide adds GIP and glucagon receptor activity, providing researchers with a tool to study multi-pathway metabolic interactions.
vs. Tirzepatide (Dual Agonist)
Tirzepatide targets both GLP-1 and GIP receptors, making it a dual-agonist. Retatrutide adds glucagon receptor agonism as a third mechanism. Published comparative analyses suggest that the addition of glucagon receptor activity may contribute to distinct metabolic effects, particularly in hepatic lipid metabolism research.
Research Applications
Retatrutide is being studied in several research contexts:
- Metabolic pathway analysis involving multi-receptor crosstalk
- Incretin biology and receptor pharmacology studies
- Comparative studies against single and dual-agonist peptides
- Hepatic lipid metabolism research (glucagon receptor component)
- Energy expenditure pathway investigations
Handling and Storage for Research Use
For researchers working with retatrutide:
- Storage: -20°C in lyophilized form, protected from light
- Reconstitution: Use bacteriostatic water for multi-use protocols
- Post-reconstitution: Store at 2-8°C, use within 30 days
- Purity verification: HPLC analysis recommended; research-grade material should meet ≥98% purity
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metabolism. 2022;34(9):1234-1247.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526.
- Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial. The Lancet. 2023;402(10401):529-544.
This article is provided for informational and educational purposes only. All Silicon Valley Peptides products are sold strictly for in-vitro research and laboratory use. They are not intended for human consumption, therapeutic use, or diagnostic purposes. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
Looking for research-grade retatrutide? View our Retatrutide research peptide available in 10mg and 30mg vials.
